Taiwan team research reduces antibody drug side effects

07/10/2019 07:25 PM
To activate the text-to-speech service, please first agree to the privacy policy below.
Cheng Tian-lu (鄭添祿, front, right)
Cheng Tian-lu (鄭添祿, front, right)

Taipei, July 10 (CNA) A team from Kaohsiung Medical University (KMU) has obtained patents in several countries for groundbreaking research that enhances the selectivity and safety of antibody drugs, the school announced at a press conference Wednesday.

The research team has applied for patents in 15 countries for the technological invention, which uses autologous hinge as a universal antibody lock (ab lock) to enhance the selectivity and safety of antibody drugs, thereby effectively reducing the side effects of antibodies.

The work has already received patents in Taiwan, Japan and Australia, according to KMU President Chung Yu-chih (鐘育志).

The ab lock was developed by a research team led by Cheng Tian-lu (鄭添祿), the head of KMU research and development office and a professor from the university's Department of Biomedical Science and Environmental Biology. It won the National Innovation Award and was published in the international journal PLoS Biology in mid-June, Chung said.

The research is expected to benefit patients who take antibody drugs by reducing their side effects, Chung added.

Meanwhile, Cheng noted antibody drugs are a powerful new treatment option and one of the most often used and popular medicines, with an annual output value of more than US$100 billion worldwide.

However, with their side effects, 24 percent of anti-body drugs fail to pass clinical tests, Cheng said, adding that the ab lock will ensure patients suffer fewer side-effects from such drugs.

The research has attracted the interest of pharmaceutical manufacturing companies from Taiwan, the United States and Japan and the research team is currently seeking cooperation from interested companies, Cheng said, adding that it could create US$10 billion in business opportunities.

The technological invention was completed after seven years of research and development work by a 30-member team made up of experts from the biomedical, biotech, genome engineering and clinical medical sectors, Cheng added.

(By Wang Shwu-fen and Evelyn Kao)


    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.